COMPANY

RyCarma Therapeutics

Keywords: rare disease cardiovascular Autosomal Dominant RYR1-Related Myopathy Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 RYR-1 Myopathy Surlorian S48168 (ARM210) S48168

Location: Boston, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

Sep 9, 2026 Trial start Phase 2: A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy source ↗
Aug 1, 2023 Trial start Phase 2: Treatment of an Inherited Ventricular Arrhythmia source ↗
Aug 25, 2020 Trial start Phase 1: S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM) source ↗

Upcoming milestones

Aug 27, 2027 (ESTIMATED) · Phase 2 · A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy · NCT07560020

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07560020	A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy	Phase 2	Recruiting	Sep 9, 2026	Aug 27, 2027 (estimated)
NCT05122975	Treatment of an Inherited Ventricular Arrhythmia	Phase 2	Terminated	Aug 1, 2023	Apr 1, 2024 (actual)
NCT04141670	S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)	Phase 1	Completed	Aug 25, 2020	Dec 30, 2022 (actual)